Sionna's SION-719 CF Program Misses Key Endpoint
Sionna missed the key activity endpoint for the SION-719 proof-of-concept trial, canceling development as an add-on to Trikafta. Despite the setback, the company maintains strong cash reserves and advanced its NBD1 dual combination trial.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day